Invited Review Recognition and management of angiotensin converting enzyme inhibitor fetopathy

Show simple item record

dc.contributor.author Bunchman, Timothy E. en_US
dc.contributor.author Sedman, Aileen B. en_US
dc.contributor.author Kershaw, David B. en_US
dc.date.accessioned 2006-09-11T19:26:52Z
dc.date.available 2006-09-11T19:26:52Z
dc.date.issued 1995-06 en_US
dc.identifier.citation Sedman, Aileen B.; Kershaw, David B.; Bunchman, Timothy E.; (1995). "Invited Review Recognition and management of angiotensin converting enzyme inhibitor fetopathy." Pediatric Nephrology 9(3): 382-385. <http://hdl.handle.net/2027.42/47835> en_US
dc.identifier.issn 0931-041X en_US
dc.identifier.issn 1432-198X en_US
dc.identifier.uri http://hdl.handle.net/2027.42/47835
dc.identifier.uri http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=7632538&dopt=citation en_US
dc.description.abstract Angiotensin converting enzyme (ACE) inhibitors are extensively used for the treatment of hypertension, to decrease proteinuria, and to mitigate hyperfiltration. These drugs now have been shown to be fetotoxic causing profound fetal hypotension, renal tubular dysplasia, anuria-oligohydramnios, growth restriction, hypocalvaria, and death when used in the second and third trimesters of pregnancy. We recommend that ACE inhibitors not be used in pregnancy. However, if a child is born with ACE inhibitor fetopathy, aggressive therapy with dialysis to remove the inhibitor may mitigate the profound hypotensive effects. Therapy will depend on the specific ACE inhibitor, and care recommendations cannot be generalized for the entire class of drugs as their protein binding and volume of distribution differ substantially. en_US
dc.format.extent 421573 bytes
dc.format.extent 3115 bytes
dc.format.mimetype application/pdf
dc.format.mimetype text/plain
dc.language.iso en_US
dc.publisher Springer-Verlag; IPNA en_US
dc.subject.other Therapy en_US
dc.subject.other Pediatrics en_US
dc.subject.other Angiotensin Converting Enzyme Inhibitors en_US
dc.subject.other Medicine & Public Health en_US
dc.subject.other Fetopathy en_US
dc.title Invited Review Recognition and management of angiotensin converting enzyme inhibitor fetopathy en_US
dc.type Article en_US
dc.subject.hlbsecondlevel Public Health en_US
dc.subject.hlbsecondlevel Pediatrics en_US
dc.subject.hlbsecondlevel Internal Medicine and Specialties en_US
dc.subject.hlbtoplevel Health Sciences en_US
dc.description.peerreviewed Peer Reviewed en_US
dc.contributor.affiliationum Pediatric Nephrology Service, University of Michigan Medical Center, Simpson Road East, Box 0297-L2602, 1521, Ann Arbor, MI, 48109-0297, USA en_US
dc.contributor.affiliationum Pediatric Nephrology Service, University of Michigan Medical Center, Simpson Road East, Box 0297-L2602, 1521, Ann Arbor, MI, 48109-0297, USA en_US
dc.contributor.affiliationum Pediatric Nephrology Service, University of Michigan Medical Center, Simpson Road East, Box 0297-L2602, 1521, Ann Arbor, MI, 48109-0297, USA en_US
dc.contributor.affiliationumcampus Ann Arbor en_US
dc.identifier.pmid 7632538 en_US
dc.description.bitstreamurl http://deepblue.lib.umich.edu/bitstream/2027.42/47835/1/467_2005_Article_BF02254221.pdf en_US
dc.identifier.doi http://dx.doi.org/10.1007/BF02254221 en_US
dc.identifier.source Pediatric Nephrology en_US
dc.owningcollname Interdisciplinary and Peer-Reviewed
 Show simple item record

This item appears in the following Collection(s)


Search Deep Blue

Advanced Search

Browse by

My Account

Information

Available Now


MLibrary logo